Cargando…

Evidence of clinical benefit of WHO essential anticancer medicines for children, 2011–2021

BACKGROUND: Access to essential cancer medicines is a key determinant of childhood cancer survival. WHO published the Model List of Essential Medicine for Children (EMLc) and updated it every two years since 2007 to promote better access to medicines for children. This study aimed to assess whether...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bai, Lin, Zhan, Yuqi, Zhou, Yue, Zhang, Yichen, Shi, Luwen, Gupta, Sumit, Denburg, Avram, Guan, Xiaodong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10130597/ https://www.ncbi.nlm.nih.gov/pubmed/37125406 http://dx.doi.org/10.1016/j.eclinm.2023.101966

Ejemplares similares

Overall survival benefits of cancer drugs in the WHO Model List of Essential Medicines, 2015–2021
por: Zhou, Yue, et al.
Publicado: (2023)

Access to WHO Essential Medicines for Childhood Cancer Care in Trinidad and Tobago: A Health System Analysis of Barriers and Enablers
por: Tang, Brandon, et al.
Publicado: (2020)

Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China
por: Zhang, Yichen, et al.
Publicado: (2022)

Health system determinants of access to essential medicines for children with cancer in Ghana
por: Boateng, Rhonda, et al.
Publicado: (2020)

A survey of availability, price and affordability of essential medicines from 2011 to 2016 in Chinese secondary and tertiary hospitals
por: Guan, Xiaodong, et al.
Publicado: (2018)

The impact of government reimbursement negotiation on targeted anticancer medicines use and cost in China: A cohort study based on national health insurance data
por: Yang, Yu, et al.
Publicado: (2023)

Anticancer medicines in China: Trends in daily therapy cost and relative procurement volume and spending
por: Huang, Tao, et al.
Publicado: (2021)

Trends of Negotiated Targeted Anticancer Medicines Use in China: An Interrupted Time Series Analysis
por: Huang, Cong, et al.
Publicado: (2021)

Differences in reimbursement listing of anticancer therapies in China: an observational study
por: Guan, Xiaodong, et al.
Publicado: (2020)

The impacts of implementation of National Essential Medicines Policies on primary healthcare institutions: a cross-sectional study in China
por: Guo, Zhigang, et al.
Publicado: (2017)

The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China
por: Zhang, Yichen, et al.
Publicado: (2021)

Factors Associated with Free Medicine Use in Patients with Hypertension and Diabetes: A 4-Year Longitudinal Study on Full Coverage Policy for Essential Medicines in Taizhou, China
por: Guo, Zhigang, et al.
Publicado: (2021)

Effects of the Full Coverage Policy of Essential Medicines on Inequality in Medication Adherence: A Longitudinal Study in Taizhou, China
por: Guo, Zhigang, et al.
Publicado: (2022)

Health technology assessment-informed pricing negotiation in China: higher negotiated price for more effective targeted anticancer medicines?
por: Huang, Cong, et al.
Publicado: (2022)

Cost and cost-effectiveness of childhood cancer treatment in low-income and middle-income countries: a systematic review
por: Fung, Alastair, et al.
Publicado: (2019)

Effect of the full coverage policy of essential medicines on medication adherence: A quasi-experimental study in Taizhou, China
por: Guo, Zhigang, et al.
Publicado: (2022)

Evidence From Ghana Indicates That Childhood Cancer Treatment in Sub-Saharan Africa Is Very Cost Effective: A Report From the Childhood Cancer 2030 Network
por: Renner, Lorna, et al.
Publicado: (2018)

Overall Survival Benefits of Cancer Drugs Approved in China From 2005 to 2020
por: Zhang, Yichen, et al.
Publicado: (2022)

Evaluation of a Health Care Worker Training Intervention to Improve the Early Diagnosis and Referral of Childhood Cancers in Ghana: A Qualitative Descriptive Study
por: Fowokan, Adeleke, et al.
Publicado: (2022)

Secular trend analysis of antibiotic utilisation in China’s hospitals 2011–2018, a retrospective analysis of procurement data
por: Wushouer, Haishaerjiang, et al.
Publicado: (2020)

Medical insurance and healthcare utilization among the middle-aged and elderly in China: evidence from the China health and retirement longitudinal study 2011, 2013 and 2015
por: Zhou, Yue, et al.
Publicado: (2020)

WHO essential medicines for reproductive health
por: Gill, Roopan, et al.
Publicado: (2019)

Monographs for medicines on WHO’s Model List of Essential Medicines
por: Roth, Lukas, et al.
Publicado: (2018)

Accessibility of essential anticancer medicines for children in the Sichuan Province of China
por: Chen, Zhe, et al.
Publicado: (2022)

Access and use of WHO essential medicines in Italy
por: Petrella, Alessandro, et al.
Publicado: (2023)

Medicines for cancers in children: The WHO model for selection of essential medicines
por: Robertson, Jane, et al.
Publicado: (2015)

Inpatient antibacterial use trends and patterns, China, 2013–2021
por: Wushouer, Haishaerjiang, et al.
Publicado: (2023)

Selection of WHO-recommended essential medicines for non-communicable diseases on National Essential Medicines Lists
por: Jarvis, Jordan D., et al.
Publicado: (2019)

Special Issue “Anticancer Drugs 2021”
por: Meegan, Mary J., et al.
Publicado: (2022)

Essential medicines for cancer: WHO recommendations and national priorities
por: Robertson, Jane, et al.
Publicado: (2016)

Availability of WHO Essential Medicines for Cancer Treatment in Botswana
por: Martei, Yehoda M., et al.
Publicado: (2018)

Revising the WHO Essential Medicines List for paediatric rheumatology
por: Scott, Christiaan, et al.
Publicado: (2021)

A comparative analysis of the Libyan national essential medicines list and the WHO model list of essential medicines
por: Mustafa, Asma Abubakr, et al.
Publicado: (2010)

Tularemia Transmission to Humans, the Netherlands, 2011–2021
por: Rijks, Jolianne M., et al.
Publicado: (2022)

Defining Essential Childhood Cancer Medicines to Inform Prioritization and Access: Results From an International, Cross-Sectional Survey
por: Denburg, Avram E., et al.
Publicado: (2022)

An Up-To-Date Review Regarding Cutaneous Benefits of Origanum vulgare L. Essential Oil
por: Bora, Larisa, et al.
Publicado: (2022)

Global status of essential medicine selection: a systematic comparison of national essential medicine lists with recommendations by WHO
por: Piggott, Thomas, et al.
Publicado: (2022)

Estimation of cost-based prices for injectable medicines in the WHO Essential Medicines List
por: Gotham, Dzintars, et al.
Publicado: (2019)

The Impact of WHO Essential Medicines Policies on Inappropriate Use of Antibiotics
por: Holloway, Kathleen Anne, et al.
Publicado: (2016)

Mechanistic Insights on the Mechanosynthesis of Phenytoin, a WHO Essential Medicine
por: Puccetti, Francesco, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_23og092q2ohvfkdsakbmvmbnte